- Home
- ORC vs CRGX Comparison
ORC vs CRGX Comparison
Compare ORC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- CRGX
- Stock Information
- Founded
- ORC 2010
- CRGX 2021
- Country
- ORC United States
- CRGX United States
- Employees
- ORC N/A
- CRGX N/A
- Industry
- ORC Real Estate Investment Trusts
- CRGX
- Sector
- ORC Real Estate
- CRGX
- Exchange
- ORC Nasdaq
- CRGX Nasdaq
- Market Cap
- ORC 623.6M
- CRGX 628.6M
- IPO Year
- ORC 2013
- CRGX 2023
- Fundamental
- Price
- ORC $8.28
- CRGX $3.70
- Analyst Decision
- ORC Buy
- CRGX Hold
- Analyst Count
- ORC 3
- CRGX 7
- Target Price
- ORC $9.50
- CRGX $4.67
- AVG Volume (30 Days)
- ORC 3.0M
- CRGX 1.9M
- Earning Date
- ORC 01-30-2025
- CRGX 03-20-2025
- Dividend Yield
- ORC 17.43%
- CRGX N/A
- EPS Growth
- ORC N/A
- CRGX N/A
- EPS
- ORC 0.58
- CRGX N/A
- Revenue
- ORC $54,406,000.00
- CRGX N/A
- Revenue This Year
- ORC N/A
- CRGX N/A
- Revenue Next Year
- ORC N/A
- CRGX N/A
- P/E Ratio
- ORC $14.41
- CRGX N/A
- Revenue Growth
- ORC N/A
- CRGX N/A
- 52 Week Low
- ORC $7.41
- CRGX $3.00
- 52 Week High
- ORC $9.08
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- ORC 62.14
- CRGX 20.88
- Support Level
- ORC $7.88
- CRGX $3.00
- Resistance Level
- ORC $8.38
- CRGX $3.88
- Average True Range (ATR)
- ORC 0.18
- CRGX 0.92
- MACD
- ORC 0.04
- CRGX -1.00
- Stochastic Oscillator
- ORC 81.51
- CRGX 5.99
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.